Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Spin-Off Asuragen Raises $49M in Series A Funding

NEW YORK (GenomeWeb News) - Ambion spin-off Asuragen has raised $49 million in a Series A private-equity financing round, the company said today.

It will use the cash to help pay for operating expenses and to license its cancer diagnostic and therapeutic programs.
 
Telegraph Hill Partners led the round, which included Growth Capital Partners and other firms that invested in Ambion, the company said.
 
Asuragen was formed after Applied Biosystems  acquired Ambion's RNA business in March. It comprises Ambion's former diagnostics and services division as well as a discovery group.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.